Nobody Told Us This Was M&A Week
Most important take away
A wave of massive M&A deals hit the food industry and pharmaceuticals this week, with Cisco acquiring Restaurant Depot for $26 billion and McCormick merging with Unilever’s food division for $44 billion. The hosts caution that consumer brands M&A has a poor track record of creating shareholder value, with most major deals over the past decade destroying value rather than building it, making the debt loads these companies are taking on a key risk to watch.
Summary
Stocks and Investments Mentioned:
- Cisco (food distributor) — Acquiring Restaurant Depot for $26 billion, taking on $21 billion in new debt. The hosts view this as the more promising of the two food deals due to the strategic fit of adding a new customer segment (flexible, price-conscious restaurant owners).
- McCormick — Merging with Unilever’s food division in a $44 billion reverse Morris Trust deal. McCormick itself is only a $14 billion company, making this highly transformative and risky. The hosts are skeptical given the poor track record of mid-tier consumer brand M&A.
- Performance Food Group (PFGC) — Cited as a positive example of acquisition-driven growth in food distribution, up 160% since 2019 after acquiring three major competitors including Cheney Brothers.
- Eli Lilly — Acquiring Centessa Pharmaceuticals for up to $7.8 billion (contingent on FDA milestones). The deal targets a narcolepsy treatment estimated to address a $5 billion market. This is a strategic diversification move since ~60% of Lilly’s revenue currently comes from GLP-1 drugs.
- Centessa Pharmaceuticals — Clinical-stage company with a promising narcolepsy treatment that passed Phase 2 trials. Only 20-30% of Phase 2 drugs ultimately receive FDA approval.
- Whirlpool (WHR) — Trading at 9.3x trailing earnings with a 6.9% dividend yield. Stock is down 50%+ from highs. The hosts are lukewarm: the dividend was already cut in half last year, a dilutive capital raise in February dropped shares 15%, and a sluggish housing market limits recovery potential. Not recommended as a long-term hold.
Actionable Insights:
- Be wary of large consumer brand M&A deals — The track record over the past decade (Kraft Heinz, AB InBev/SAB Miller, Keurig/Dr Pepper) has been poor. Mid-tier brands are being squeezed as consumers either pay up for premium or buy generic, making scale-through-acquisition strategies less effective.
- Watch debt paydown timelines on both the Cisco and McCormick deals — how quickly they reduce leverage will determine whether these acquisitions create or destroy value.
- For pharma investing, favor companies with multiple pipeline candidates rather than betting on single drugs, since only 20-30% of Phase 2 candidates reach market.
- Don’t overweight political/regulatory risk in pharma — Drug development cycles span a decade or more, outlasting any single administration. Focus on the science rather than political winds.
- Whirlpool is not a buy-and-forget stock — While the valuation looks cheap and the dividend is currently covered, the housing market headwinds and management’s willingness to cut the dividend make it a speculative recovery play at best.
Chapter Summaries
Food Industry M&A Mania — Cisco is acquiring Restaurant Depot for $26 billion and McCormick is merging with Unilever’s food division for $44 billion. The hosts discuss how Cisco’s deal has stronger strategic logic (adding a complementary customer channel) while McCormick’s reverse Morris Trust structure is financially interesting but faces headwinds from the deteriorating value of mid-tier consumer brands. Performance Food Group (PFGC) is highlighted as a rare example of successful food distribution M&A.
Eli Lilly Acquires Centessa Pharmaceuticals — Lilly is paying up to $7.8 billion for Centessa’s narcolepsy treatment pipeline, with full payment contingent on FDA approval milestones. The deal represents Lilly’s effort to diversify beyond GLP-1 drugs, which currently drive 60% of revenue. The hosts discuss the inherent risks of clinical-stage pharma investing and note that FDA regulatory changes under the current administration add uncertainty but should not dominate long-term investment decisions.
Listener Question: Whirlpool (WHR) — A listener asks about Whirlpool’s investment thesis given its high dividend yield and debt load. The hosts agree the stock is cheap (9.3x earnings, 6.9% yield) but express concern about the sluggish housing market, a recent dilutive capital raise, and a dividend that was already halved. They see a possible trading opportunity but not a compelling long-term investment.